VIVUS, Inc. (VVUS) News
Filter VVUS News Items
VVUS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest VVUS News From Around the Web
Below are the latest news stories about Vivus Inc that investors may wish to consider to help them evaluate VVUS as an investment opportunity.
Vivus moves closer to emerging from bankruptcyVivus (VVUS) plummets 26% premarket after completing the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma will take 100% ownership of the company (the “Prepackaged Plan”), ahead of its Chapter 11 filing.The company solicited IEH as the only holder of claims and has received IEH’s voting in favor of... |
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For BankruptcyHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma... |
VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLCVIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020. |
VVUS: Enterprise Valuation UpdateBy John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and |
Vivus files for equity offeringVIVUS (VVUS) has filed a preliminary prospectus for a public offering of stock and warrants of up to ~$186M. Prices, volumes and terms have yet to be determined.Shares down 3% premarket on light volume.... |
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes. Under the terms of the agreement, the Company will continue to work with IEH Biopharma on an exclusive basis in respect of any restructuring, financing or other material transaction concerning the Company or its assets, with the exception that the Company is granted a 30-day period to refinance and pay in full in cash all amounts due and owing under the Convertible Senior Notes to IEH Biopharma. |
Edited Transcript of VVUS earnings conference call or presentation 6-May-20 8:30pm GMTQ1 2020 Vivus Inc Earnings Call |
VVUS: First Quarter 2020 ResultsBy John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) released first quarter 2020 results on May 6, 2020 and provided an update of financial and operational results for the period. During the first quarter of the year, total revenues were up 22% to $19.6 million on a year over year basis and up 14% sequentially. First quarter earnings were ($0.49) per share and adjusted earnings ($0.15) |
VIVUS Reports First Quarter 2020 Financial ResultsCompany to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a… |
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate DebtCAMPBELL, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement… |